title: Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda.
abstract: OBJECTIVE
  To assess willingness to participate in HIV vaccine trials and possible barriers to participation.
  
  
  METHODS
  Questionnaire survey of participants completing a 2-year community-based HIV Vaccine Preparedness Study, followed by cross sectional analysis of data.
  
  
  RESULTS
  95% of participants were willing to participate in a trial with similar attributes to the Vaccine Preparedness Study. Certain hypothetical trial attributes significantly reduced willingness to participate: The requirement to delay pregnancy (for females) had the largest effect, reducing willingness to participate from 97% to 23% (P < 0.0001). Larger blood draws had the second largest effect: 95-55% (P < 0.0001). The possibility of receiving either candidate vaccine or placebo had the third largest effect: 95-73% (P < 0.0001). Monthly study visits had the fourth largest effect: 95-92% (P < 0.0001). Trial duration longer than 2 years had the least effect: 95-93% (P = 0.0025). Combined attributes reduced willingness to participate from 95% to 43% (McNemar's chi(2) = 521.00; P < 0.0001) overall and 97-11% (McNemar's chi(2) = 531.00; P < 0.0001) for female participants. Physical harm concerns (adjusted OR = 34.9; 95% CI, 10.4-118) and a low risk behaviour index (adjusted OR = 0.09; 95% CI, 0.01-0.73) were associated with unwillingness to participate.
  
  
  CONCLUSIONS
  We found a high level of willingness to participate in HIV vaccine trials in this population. However, certain HIV vaccine trial requirements were associated with reduced willingness to participate. Community as well as individual concerns will have to be carefully addressed in planned HIV vaccine trials.
authors.affiliation: Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) Uganda Research Unit on AIDS, Entebbe, Uganda. eugene.ruzagira@mrcuganda.org
authors.forename: Eugene
authors.initials: E
authors.lastname: Ruzagira
authors.forename: Symon
authors.initials: S
authors.lastname: Wandiembe
authors.forename: Leonard
authors.initials: L
authors.lastname: Bufumbo
authors.forename: Jonathan
authors.initials: J
authors.lastname: Levin
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Price
authors.forename: Heiner
authors.initials: H
authors.lastname: Grosskurth
authors.forename: Anatoli
authors.initials: A
authors.lastname: Kamali
mesh_terms: D016915:AIDS Vaccines; D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003256:Community Participation; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D009042:Motivation; D011795:Surveys and Questionnaires; D014454:Uganda; D055815:Young Adult
chemical_list: D016915:AIDS Vaccines